Non-Drug ADHD Treatments Don't Pan Ou... ( By Barbara Bronson Gray HealthDa...)

Non-Drug ADHD Treatments Don't Pan Out in Study

Date:1/30/2013

By Barbara Bronson Gray
HealthDay Reporter

WEDNESDAY, Jan. 30 (HealthDay News) -- Many parents pursue costly and time-consuming treatments to help their children with attention-deficit/hyperactivity disorder. Now, a new study finds little evidence that non-drug interventions reduce key symptoms of ADHD.

A multinational team of experts identified no positive effects from psychological treatments including mind exercises (cognitive training), neurofeedback and behavioral training (positive reinforcement). And the researchers discovered only small benefits associated with dietary treatments: supplementation with omega-3 and omega-6 free fatty acids, and elimination of artificial food coloring.

Still, parents shouldn't be discouraged, said study co-author Dr. Emily Simonoff.

"I think our findings allow a much more informed discussion than did previous work because we've been able to demonstrate that what we once thought worked is more limited and more questionable," said Simonoff, a professor of child and adolescent psychiatry at King's College London.

Simonoff thinks the study conclusions need to be interpreted in the context of a child's particular situation.

"I think people need to talk with their child's clinician," she said. "Evidence is never a substitute for having a discussion about your own child and what is right for your child and your family."

ADHD diagnoses are on the rise. Between 1997 and 2007, diagnoses among U.S. children and teens increased between 3 percent and 6 percent a year, according to the U.S. Centers for Disease Control and Prevention. According to the American Psychiatric Association, between 3 percent and 7 percent of U.S. children have the condition, which makes it hard to focus in school and to sustain friendships. Currently, a combination of medication and behavior therapy is the recommended treatment, according to the CDC.

The new review, an analysi
'/>"/>

0

GOOD

Page: 1 2 3
Related medicine news :

1. Feelings of immaturity accompany alcohol misuse into adulthood; discovery could improve treatments
2. Research May Point to New Obesity Treatments
3. Researchers make promising discovery in pursuit of effective lymphoma treatments
4. Study examines treatments for relieving breathing difficulties among patients with lung effusions
5. LA BioMeds Dr. Patricia Dickson researching treatments for neurodegenerative disorders
6. Pre-op Treatments Boost Survival for Esophageal Cancer Patients: Study
7. 1960s-era anti-cancer drug points to treatments for Lou Gehrigs disease
8. Rejuv Medical In Sartell, MN Now Offering Stem Cell Treatments
9. MDS researchers join forces to advance patient treatments and outcomes
10. New Treatments Emerging from Immune and Inflammatory Disease R&D Pipelines
11. Few Migraine Sufferers Referred for Behavioral Treatments

Post Your Comments:

Related Image:

Non-Drug ADHD Treatments Don't Pan Out in Study

(Date:5/21/2013)... (PRWEB) May 21, 2013 AAG Health, ... in Miami, announced today that it has acquired the ... Physioquanta Group. , Using advanced spectrophotometry technology, the OligoScan ... bioavailability of up to 14 heavy metals, 20 trace ... of high toxic metal substances such as mercury, lead, ...

(Date:5/21/2013)... -- Racial disparities exist in the treatment of non-small ... according to a large new study. Although most ... their initial treatment, researchers found that blacks were less ... the early stages of the disease. Hispanics were more ... 2 disease than white patients. "In our study ...

(Date:5/21/2013)... PHILADELPHIA ─ A novel approach to obstructing the ... asthma has shown promise in a Phase IIa ... Their research will be presented at the American ... online in the New England Journal of ... tested the efficacy and safety of the monoclonal ...

(Date:5/21/2013)... This October, Phoenix, Arizona will host ... by Kolbe Corp, the Conation Nation Symposium ... inspire attendees to take action on these strengths in ... and 11th, will feature keynote speakers such as General ... Education for Kansas where Kolbe is widely used, and ...

(Date:5/21/2013)... (PRWEB) May 21, 2013 Canadian-based FundRazr ... hot topic. Announced today, FundRazr has accumulated a list ... our $25 Million raised milestone this week. Among them ... that raised over $1 Million from video gamers, on-going ... Julian Assange, as well as Tiger Woods sending underserved ...

Breaking Medicine News(10 mins):Health News:AAG Health is the First Age Management Center in Florida to Offer the OligoScan 2 Health News:AAG Health is the First Age Management Center in Florida to Offer the OligoScan 3 Health News:Racial Disparities Seen in U.S. Lung Cancer Treatment 2 Health News:Monoclonal antibody appears effective and safe in asthma Phase IIa trial 2 Health News:Monoclonal antibody appears effective and safe in asthma Phase IIa trial 3 Health News:A New Destination for Thought Leaders - Kolbe Corp's Conation Nation Symposium 2

[0] AAG Health is the First Age Management Center in Florida to Offer the OligoScan [0] Racial Disparities Seen in U.S. Lung Cancer Treatment [0] Monoclonal antibody appears effective and safe in asthma Phase IIa trial [0] A New Destination for Thought Leaders - Kolbe Corp's Conation Nation Symposium [0] 25 Amazing Crowdfunding Stories Highlight FundRazr's $25 Million Milestone

... Annual Dinner, May 17, DETROIT, Jan. 31 ... its nurse paging system, thanks to the,generosity of ... vice,president of development for the Institute., (Logo:, ... our 26th Annual Dinner May 17, Ford Motor ...

... Long-time local partners cite proprietary research, strategic planning and ... superior creative as keys to their success, ... two major,national advertising awards at the Consumer Health World Conference ... have again taken top honors in a national awards program., ...

... once looked at for cancer, also attacks the human immunodeficiency ... research published today online in the open access journal Retrovirology. ... learned to hide out in certain human cells where it ... serve as viral reservoirs. Operating from these havens, the virus ...

... ABAX ), a medical products company manufacturing point-of-care,blood analysis ... 31, 2007., Highlights for the third ... $25.7 million, up 17% over last year,s comparable quarter. ... over last year,s comparable quarter. ...

... Separate Research Confirms Part D Seniors Also Enjoy Broad ... Pharmaceutical Care,Management Association (PCMA) issued the following statement on ... drug benefit is lower over the,next ten years than ... saving money without sacrificing beneficiaries,choice of prescription drugs. New ...

... of its ongoing efforts to do whatever it takes ... for Parkinson,s disease, The Michael J. Fox Foundation for ... total funding to four industry teams seeking to push ... awards were granted under MJFF,s Therapeutics Development Initiative (TDI) ...

Ford Motor Company Fund Continues Longtime Support to Cancer Care St.Vincent and Publicis Indianapolis Receive National Service Industry Advertising Awards Anti-parasite drug may provide new way to attack HIV Abaxis Reports Record Sales for the Third Quarter of Fiscal 2008 CMS: Part D Costs $117 Billion Lower Than Expected Michael J. Fox Foundation awards up to $3 million to industry teams

(Date:5/21/2013)... May 21, 2013 Accuray Incorporated ... publication of study results involving hundreds of prostate ... System, the most widely used form of prostate ... 304 patients for a median of 5 years, ... that 97 percent of patients with low-risk and ...

(Date:5/21/2013)... ORLANDO, Fla. , May 21, 2013 /PRNewswire/ ... and safety results from the global Phase 3 ... protease inhibitor simeprevir (TMC435) led to sustained virologic ... (SVR12) in 79 percent of treatment-experienced genotype 1 ... disease, including all stages of liver fibrosis, when ...

(Date:5/21/2013)... 21, 2013 Abaxis, Inc. (NasdaqGS: ABAX), a ... today that Martin Mulroy , chief ... Dental & Veterinary Conference on Wednesday, May 29, 2013 ... at Le Parker Meridien Hotel in New ... Abaxis develops, manufactures, markets and sells portable blood ...

Breaking Medicine Technology:New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 2 New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 3 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7 Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2

[0] New Data Validates CyberKnife SBRT for Prostate Cancer Treatment [0] Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients [0] Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference

... Results from the Phase II portion of a ... for the treatment of acute heart failure will be ... at the American College of Cardiology,s (ACC) 58th Annual ... of medicine, University of California San Francisco , ...

... Will Test Ability of Adecatumumab to Prolong Disease ... MetastasesBETHESDA, Md., March 23 Micromet, ... company developing novel, proprietary antibodies for the treatment ... the commencement of a randomized, controlled phase 2 ...

Cached Medicine Technology:Results From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session 2 Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients 2 Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients 3 Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients 4 Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients 5

Results From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients

...

Tip is bent towards port for downward irrigation. 25G x 5/8in (.50 x 22mm)...

... product designed for LASIK surgery and other ... the corneal interface and/or stromal bed. Flattened ... and helps elevate the flap edge. Multiple ... G (.40 x 22mm). Angled 90 degrees, ...

... LASIK surgery and other types of ... corneal interface and/or stromal bed. Flattened ... flap and helps elevate the flap ... 23G x 7/8in (.60 x 22mm) ...

Medicine Products:

Hydrodissector - Daya Irrigating Cystotome - Reverse Lasik Irrigator - Probst Lasik Spatula/Irrigator